CL2021001958A1 - Procedimiento de fabricación continuo para la fabricación de productos biológicos mediante integración de procedimientos de principio activo y producto terminado. - Google Patents

Procedimiento de fabricación continuo para la fabricación de productos biológicos mediante integración de procedimientos de principio activo y producto terminado.

Info

Publication number
CL2021001958A1
CL2021001958A1 CL2021001958A CL2021001958A CL2021001958A1 CL 2021001958 A1 CL2021001958 A1 CL 2021001958A1 CL 2021001958 A CL2021001958 A CL 2021001958A CL 2021001958 A CL2021001958 A CL 2021001958A CL 2021001958 A1 CL2021001958 A1 CL 2021001958A1
Authority
CL
Chile
Prior art keywords
active ingredient
finished product
manufacturing process
integration
manufacture
Prior art date
Application number
CL2021001958A
Other languages
English (en)
Inventor
Balakumar Thangaraj
Malhar R Ambhaikar
Vincent Chai
Philip Clark
Subramanian GUHAN
Sai Chakradhar Padala
Nitin Rathore
Zane Saremi
Ashish Sharma
Kenneth Shoemaker
John E Thorup
Benjamin J Tillotson
Hann-Chung Wong
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2021001958A1 publication Critical patent/CL2021001958A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B01D61/146—Ultrafiltration comprising multiple ultrafiltration steps
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D63/00—Apparatus in general for separation processes using semi-permeable membranes
    • B01D63/02—Hollow fibre modules
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
    • B01D71/06—Organic material
    • B01D71/30—Polyalkenyl halides
    • B01D71/32—Polyalkenyl halides containing fluorine atoms
    • B01D71/34—Polyvinylidene fluoride
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2315/00—Details relating to the membrane module operation
    • B01D2315/16—Diafiltration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2317/00—Membrane module arrangements within a plant or an apparatus
    • B01D2317/02—Elements in series
    • B01D2317/022—Reject series
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Abstract

Un procedimiento de fabricación de productos biológicos que conecta los procedimientos de principio activo y producto terminado en un procedimiento continuo, integrado.
CL2021001958A 2019-01-28 2021-07-26 Procedimiento de fabricación continuo para la fabricación de productos biológicos mediante integración de procedimientos de principio activo y producto terminado. CL2021001958A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962797445P 2019-01-28 2019-01-28

Publications (1)

Publication Number Publication Date
CL2021001958A1 true CL2021001958A1 (es) 2022-01-28

Family

ID=69740575

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2021001958A CL2021001958A1 (es) 2019-01-28 2021-07-26 Procedimiento de fabricación continuo para la fabricación de productos biológicos mediante integración de procedimientos de principio activo y producto terminado.
CL2023001293A CL2023001293A1 (es) 2019-01-28 2023-05-04 Procedimiento de fabricación para productos biológicos mediante integración de procedimientos principio activo - producto terminado

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2023001293A CL2023001293A1 (es) 2019-01-28 2023-05-04 Procedimiento de fabricación para productos biológicos mediante integración de procedimientos principio activo - producto terminado

Country Status (16)

Country Link
US (1) US20220119526A1 (es)
EP (1) EP3917494A1 (es)
JP (1) JP2022523025A (es)
KR (1) KR20210120032A (es)
CN (1) CN113382716A (es)
AR (1) AR117896A1 (es)
AU (1) AU2020216108A1 (es)
BR (1) BR112021014634A2 (es)
CA (1) CA3127258A1 (es)
CL (2) CL2021001958A1 (es)
EA (1) EA202192108A1 (es)
IL (1) IL284782A (es)
MX (1) MX2021008985A (es)
SG (1) SG11202107714VA (es)
TW (1) TW202043253A (es)
WO (1) WO2020159838A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220396599A1 (en) * 2019-11-13 2022-12-15 Amgen Inc. Method for Reduced Aggregate Formation in Downstream Processing of Bispecific Antigen-Binding Molecules
TW202140511A (zh) 2020-01-15 2021-11-01 瑞士商赫孚孟拉羅股份公司 減少來自重組蛋白生產過程中的雜質之方法
WO2024054414A1 (en) 2022-09-06 2024-03-14 Amgen Inc. Lean perfusion cell culture methods
WO2024059235A2 (en) 2022-09-16 2024-03-21 Amgen Inc. A method for harvesting products from perfusion cultures

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
AU761587B2 (en) 1998-04-21 2003-06-05 Amgen Research (Munich) Gmbh CD19xCD3 specific polypeptides and uses thereof
DE602004030811D1 (de) 2003-10-16 2011-02-10 Micromet Ag Multispezifische deimmunisierte cd3-bindende moleküle
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
ES2695047T3 (es) 2007-04-03 2018-12-28 Amgen Research (Munich) Gmbh Dominio de unión específico entre especies
ES2680151T3 (es) 2012-03-01 2018-09-04 Amgen Research (Munich) Gmbh Moléculas de unión de polipéptidos de larga duración
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
LT2970449T (lt) 2013-03-15 2019-11-25 Amgen Res Munich Gmbh Viengrandės surišančios molekulės, apimančios n galo abp
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
US11634502B2 (en) 2013-03-15 2023-04-25 Amgen Inc. Heterodimeric bispecific antibodies
EP3049440B1 (en) 2013-09-25 2020-03-25 Amgen Inc. V-c-fc-v-c antibody
WO2016005903A2 (en) * 2014-07-08 2016-01-14 Theramyt Novobiologics Private Limited A process for obtaining exendin-4
KR20180037056A (ko) * 2015-09-22 2018-04-10 화이자 인코포레이티드 치료학적 단백질 제형의 제조 방법 및 이러한 방법에 의해 생산된 항체 제형
KR20180074775A (ko) * 2015-10-26 2018-07-03 론자 리미티드 생물약제의 생산을 위한 제조 설비
EA039859B1 (ru) * 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
EP3724229A1 (en) 2017-12-11 2020-10-21 Amgen Inc. Continuous manufacturing process for bispecific antibody products

Also Published As

Publication number Publication date
BR112021014634A2 (pt) 2021-10-26
WO2020159838A1 (en) 2020-08-06
TW202043253A (zh) 2020-12-01
MX2021008985A (es) 2021-09-08
IL284782A (en) 2021-08-31
EP3917494A1 (en) 2021-12-08
CN113382716A (zh) 2021-09-10
JP2022523025A (ja) 2022-04-21
AU2020216108A1 (en) 2021-08-12
AR117896A1 (es) 2021-09-01
CA3127258A1 (en) 2020-08-06
EA202192108A1 (ru) 2021-10-21
SG11202107714VA (en) 2021-08-30
CL2023001293A1 (es) 2023-10-06
US20220119526A1 (en) 2022-04-21
KR20210120032A (ko) 2021-10-06

Similar Documents

Publication Publication Date Title
CL2021001958A1 (es) Procedimiento de fabricación continuo para la fabricación de productos biológicos mediante integración de procedimientos de principio activo y producto terminado.
USD850071S1 (en) Shoe
USD787458S1 (en) Gas supply plate for semiconductor manufacturing apparatus
USD833024S1 (en) Belt bandage
USD798917S1 (en) Laser processing machine
MX2019001982A (es) Articulos de calzado que tienen un corte que incluye un componente tricotado con una region de amortiguacion, un corte y metodos para fabricar el articulo de calzado.
MX2017011011A (es) Producto de limpieza de dosis multiples y metodo de fabricacion.
USD866621S1 (en) Laser cutting machine
MY198103A (en) Wafer processing method
USD797866S1 (en) Stationary pedal machine
AR113089A1 (es) Filtro para un artículo para fumar o un producto que genera aerosol
WO2020046717A8 (en) Method for forming a footwear midsole
CO2018007008A2 (es) "procesos mejorados para la preparación de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo"
BR112018003800A2 (pt) derivados de 1,7-diaril-1,6-heptadieno-3,5-diona, processo para a sua produção e utilização
MX2020002069A (es) Producto de tejido elaborado utilizando cinta de estructuración grabada por láser.
NI202000044S (es) Bandejas de fabricación
USD785426S1 (en) Guide bar for chain saw
GB2529599A (en) Rotary die system
USD921069S1 (en) Machine for the development and production of solid pharmaceutical products
AR103141A1 (es) Proceso para tratamiento de lana y productos
AR115642A1 (es) Preparación alimenticia
WO2018049007A8 (en) METHOD FOR KNITTING MULTIPLE RODS ON A MACHINE AND ROD FOR FOOTWEAR
CL2022002693A1 (es) Producto horneado
AR125017A4 (es) Una bandeja molde para el horneado de productos panificados
Ozkan Dr Mary Norine Walsh, President of ACC: As the new President of the American College of Cardiology (ACC), Dr Mary N. Walsh explains how she hopes her election will help advance new opportunities for women in the field